Ubs Oconnor LLC Alkermes Plc. Transaction History

Ubs Oconnor LLC

$1.72 Billion
Q2 2024

A detailed history of Ubs Oconnor LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 77,000 shares of ALKS stock, worth $2.09 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

77,000

Holding current value

$2.09 Million

% of portfolio

0.11%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $1.79 Million - $2.1 Million	77,000 New	77,000 $1.86 Million
Q4 2023 Feb 14, 2024	BUY	$23.37 - $28.68 $205,515 - $252,211	8,794 New	8,794 $243,000

Others Institutions Holding ALKS

# of Institutions

346

Shares Held

183M

Call Options Held

209K

Put Options Held

89.4K

Black Rock Inc. New York, NY

29.1M
Shares

$791 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

20M
Shares

$543 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

14.4M
Shares

$390 Million
0.06% of portfolio
Price T Rowe Associates Inc Baltimore, MD

11M
Shares

$299 Million
0.03% of portfolio
State Street Corp Boston, MA

9.22M
Shares

$250 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.46B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account